Neuroinflammation and Its Resolution: From Molecular Mechanisms to Therapeutic Perspectives by Zusso, Morena et al.
Frontiers in Pharmacology | www.frontiers








This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 06 March 2020
Accepted: 26 March 2020
Published: 08 April 2020
Citation:
Zusso M, Stokes L, Moro S
and Giusti P (2020) Editorial:
Neuroinflammation and Its Resolution:





published: 08 April 2020




Morena Zusso1*, Leanne Stokes2, Stefano Moro1 and Pietro Giusti 1
1 Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy, 2 School of Pharmacy,
University of East Anglia, Norwich, United Kingdom
Keywords: neuroinflammation, neurodegenerative diseases, microglia, cytokines, therapeutic targets
Editorial on the Research Topic
Neuroinflammation and Its Resolution: FromMolecular Mechanisms to Therapeutic Perspectives
Neuroinflammation, the complex immune response of the central nervous system (CNS), when
sustained, is a common denominator in the etiology and course of all major neurological diseases,
including neurodevelopmental, neurodegenerative, and psychiatric disorders (e.g., Alzheimer's disease,
AD; Parkinson's disease, PD; multiple sclerosis, MS; motor neuron disease; depression; autism spectrum
disorder; and schizophrenia). Cellular (microglia and mast cells, two brain-resident immune cells,
together with astrocytes) and molecular immune components (e.g., cytokines, complement and pattern-
recognition receptors) act as key regulators of neuroinflammation (Skaper et al., 2012). In response to
pathological triggers or neuronal damage, immune cells start an innate immune response with the aim to
eliminate the initial cause of injury. However, when the cellular activity becomes dysregulated, it results
in an inappropriate immune response that can be injurious and affect CNS functions. Thus, limiting
neuroinflammation andmicroglia activity represents a potential strategy to alleviate neuroinflammation-
related diseases.
The Research Topic collects 20 manuscripts, divided into five sections, that include both original
research articles and reviews of the emerging literature and explore the role of neuroinflammation in
various neurological diseases. There is particular attention dedicated to the relevant research
exploring the mechanisms and mediators involved in the resolution of neuroinflammation. Our aim
was to generate a valuable discussion contributing to identify new therapeutic targets in brain
damage and providing new drug development opportunities for the prevention and treatment of
CNS diseases involving neuroinflammation.PATHOPHYSIOLOGY OF NEUROINFLAMMATION
Guzman-Martinez et al. presented an overview of the various biochemical pathways involved in the
neuroinflammatory cascade, focusing on the role of neuroinflammation in the process of protein
alteration implicated in various neurodegenerative diseases, such as AD, PD, and Huntington
disease. Herradon et al. highlighted the crosstalk between peripheral inflammation and
neuroinflammation. The authors described cytokines such as pleiotrophin and midkine as key
mediators in modulating both peripheral inflammation and neuroinflammation and they discussed
the role of these cytokines in mediating both chronic neuroinflammatory conditions (i.e.,
neurodegenerative diseases) and peripheral inflammation. Furthermore, the existing therapeuticsin.org April 2020 | Volume 11 | Article 4801
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suggested for the development of innovative strategies that focus
on the modulation of the pleiotrophin-midkine pathway.
Oxidative stress is a critical and common feature of a wide spectrum
of CNS pathologies and has been strongly implicated in microglial
activation and neuroinflammation. Malko et al. provided an extensive
review focusing on the role of the transient receptor potential
melastatin-related 2 (TRPM2) channel, an oxidative stress-sensitive
calcium-permeable cationic channel, in the activation of microglia and
neuroinflammation. The authors emphasized that in CNS diseases
microglia-related neuroinflammation is strongly attenuated inTRPM2-
KO mice or in animals treated with a TRPM2 inhibitor. These results
suggested that microglial TRPM2 represents a prospective novel
therapeutic target for neuroinflammatory CNS diseases.
In the attempt to find new antiinflammatory treatments, Joffre
et al. described the antineuroinflammatory and neuroprotective
effects of n-3 long chain polyunsaturated fatty acids and the derived
specialized proresolving mediators, with the aim to identify
molecules derived from these fatty acids as possible protagonists
of the antiinflammatory effects of polyunsaturated fatty acids.NEUROINFLAMMATION IN AD AND
MEMORY IMPAIRMENT
AD is the most common age-related neurodegenerative disease and
is characterized by progressive memory decline and cognitive
dysfunction. The impact of chronic inflammation is of relevance
in the pathophysiology of AD, considering that subjects affected by
inflammatory diseases have an increased risk of developing AD
(Heneka et al., 2015). Dysregulated immunoactivity in AD has been
widely studied and several papers point to microglia as legitimate
drug targets in AD. In this context, Biber et al. provided a concise
and informative review that reconciled some of the most recent
updates in the understanding of microglia biology with drug
discovery, noting that the dynamic properties of microglia and
their location in the CNS make targeted small molecule therapies
relatively difficult to develop. The authors proposed several
microglia target candidates (e.g., CD33, kynurenine pathway,
Toll-like receptors, the potassium channel KCa3.1, etc.), with the
optimistic hope that one of them could be used in developing drugs
useful for AD therapy.
In the attempt to understand the mechanisms underlying the
link between neuroinflammation and AD, several authors have
studied the effects of some small molecules in animal models of AD.
Bellozi et al. evaluated the effects of a 14 days oral treatment with
dactolisib, a dual phosphatidylinositol 3 kinase (PI3K)/mammalian
target of rapamycin (mTOR) inhibitor, in a transgenic mousemodel
of AD overexpressing the amyloid precursor protein (APP). Among
the different pathways involved in the maintenance and progression
of AD, an abnormal and continuous activation of PI3K/protein
kinase B (Akt)/mTOR signaling contributes to disease progression,
because of the disrupted clearance of amyloid b (Ab) and tau,
synaptic loss, and cognitive decline (O'neill, 2013; Heras-Sandoval
et al., 2014). Dactolisib reduced social memory impairment,
microglia activation in CA3 region of hippocampus, and theFrontiers in Pharmacology | www.frontiersin.org 2levels of hippocampal interleukin (IL)-10, suggesting that an
adequate control of PI3K/Akt/mTOR pathway activation might
have the potential to ameliorate AD signs and symptoms. Ano et al.
demonstrated interesting effects of a short-term intake of iso-a-
acids, which are bitter components in beer, in the reduction of the
hippocampal inflammation and neural hyperactivation and
memory impairment in a transgenic mouse model of AD.
Considering that chronic psychosocial stress represents a risk factor
for AD, being associated with cognitive deficits, microglia priming, and
inflammatory responses in adult brain (Piirainen et al, 2017), Wang Y.
et al. focused on the relation between social stress and impairment of
learning andmemory inAD. The authors showed that icariin, a natural
flavonoid extracted from Epimedium brevicornum Maxim (a
traditional Chinese herb), attenuated restraint/isolation stress-induced
memory damage, Ab accumulation, and neuroinflammation by
reducing microglia M1 activation and activating peroxisome
proliferator-activated receptor g in APP/PS1 mice.
Alagan et al. showed the neuroprotective and antiinflammatory
effects of an ethanol extract of Phyllanthus amarus in an in vivo rat
model of lipopolysaccharide (LPS)-induced memory impairment
and neuroinflammation. Lykhmus et al. presented an interesting
study on the effects of mesenchymal stem cells (MSCs) in a mouse
model of memory impairment induced by LPS. Intravenously
injection of MSCs or their conditioned media prevented a7
nAChR decrease, Ab accumulation, and episodic memory decline
induced by a single dose of systemic LPS in mice, suggesting that
MSCs could be a potential therapeutic tool to treat
neuroinflammatory-related cognitive pathology.NEUROINFLAMMATION IN PSYCHIATRIC
DISORDERS
Increasing evidence indicates that dysregulated or enhanced
neuroinflammation is closely linked with the pathogenesis of
psychiatric disorders, such as schizophrenia, anxiety and
depression (Müller and Bechter, 2013; Weber et al., 2017). In a
timely and comprehensive review, Müller considered the role of
the intracellular adhesion molecule-1 (ICAM-1) in psychiatric
illness. ICAM-1, expressed in microglia, astrocytes, and in
endothelial cells of the CNS, is of particular interest from two
interrelated reasons: it is a cell bound adhesion molecule,
intimately associated with the blood brain barrier, and as a
soluble protein it has been measured in blood or cerebrospinal
fluid as a biomarker for several mental health disorders.
Depression is a recurrent, common, and potentially life-
threatening psychiatric disease related to multiple causes.
Hyperactivity of the hypothalamic-pituitary-adrenal axis, involved
in the pathophysiology of depression, induces microglia activation
and the overproduction of proinflammatory cytokines in the brain
(Brites and Fernandes, 2015). Extensive research in recent years has
been concentrated on the immuno-inflammatory mechanisms for
the treatment of depression. Indeed, many antidepressants are
endowed with antiinflammatory effects (Kenis and Maes, 2002).
However, current antidepressants have important limitations, due
to significant adverse reactions, poor compliance, and a high risk ofApril 2020 | Volume 11 | Article 480
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natural plant products are offering attractive alternatives in
antidepressant drug development. In this context, Ke et al.
examined the effect of quercetin, a natural polyphenol with
antiinflammatory and neuroprotective effects, in a rat model of
LPS-induced depression. The authors showed that quercetin
attenuated the inflammation induced depression-like behavior and
improved learning and memory in LPS-challenged rats. These effects
were associated with the reversal effects of quercetin on LPS-induced
alteration of expression of brain derived neurotrophic factor, Copine
6, and TREM1/2 in the hippocampus and in the prefrontal cortex.
Lee et al. found that myelophil, a 30% ethanol extract of Radix
Astragali and Radix Salviae, reversed the depressive behavior in a
mouse model of unpredictable chronic mild stress. Myelophil also
decreased the over-activation of microglia and the inflammatory
response in the hippocampus, and reversed the reduction of
serotonergic function in the dorsal raphe nuclei and neurogenesis
in the subgranular zone of hippocampus.
NEUROINFLAMMATION IN MS AND
EXPERIMENTAL AUTOIMMUNE NEURITIS
MS is a CNS autoimmune and neurodegenerative disease that affects
~2.5 million people worldwide and causes a significant financial
burden. Several experimental and clinical studies have revealed that
microglia/macrophages actively participate in the course of the
disease. In this context, Wang J. et al. provided a comprehensive
review that attempted to discuss the role of macrophages and
microglia in both healthy CNS and in MS. The authors discussed
the possibility of a differential manipulation of CNS residentmicroglia
and infiltrating macrophages to potentially target different
mechanisms operating in MS and realize efficient treatments for
the disease. Zhang F. et al. demonstrated that scopoletin, a phenolic
coumarin found in some plants, improved the severity of the disease
and prominently decreased inflammation and demyelination in an
experimental autoimmune encephalomyelitis mouse model of MS,
via nuclear factor-kB signaling.
Xu et al. examined the effect of oridonin, a diterpenoid compound
extracted from Rabdosia rubescens, in an experimental autoimmune
neuritis animal model. Oridonin ameliorated inflammatory disease
progression and favored the disease outcome by inducing the switch
of macrophages toward the antiinflammatory polarization state.
Thus, oridonin could be considered a possible therapeutic




Chronic pain is caused by nerve damage which occurs during
nerve compression, diabetes, inflammation, and shingles virus
infection (Campbell and Meyer, 2006). Cytokines, chemokines,
prostaglandins, and nitric oxide released from activatedFrontiers in Pharmacology | www.frontiersin.org 3microglia and astrocytes in the dorsal horn of the spinal cord
play important roles in the pathogenesis of chronic pain (Skaper
et al., 2018). Therefore, several studies have targeted activated
microglia to reduce pain hypersensitivity. In light of this, the
manuscript by Song et al. showed the positive effect of GNF-2, a
selective allosteric inhibitor of Bcr-Abl, initially developed as an
anticancer drug, on neuroinflammation and associated pain
pathogenesis, using different animal models of pain.
Malaguarnera et al. studied the effect of bicuculline, a GABAA
receptor antagonist, on hyperammonemic rats. In the
hippocampus of these animals, GABAergic tone was increased
contributing to some aspects of neuroinflammation. Glutamate
transmission was altered and spatial learning and memory as
well as anxiety were impaired. As expected, the treatment with
bicuculline reduced hippocampal astrocytosis, but failed to
control glial activation. Furthermore, the antagonist reduced
the GABAergic tone and reversed the expression of the GluA1
and GluA2 subunits of AMPA receptors and of the NR2B
subunit of NMDA receptors. The treatment with bicuculline
also improved spatial learning, working memory and decreased
anxiety in these rats.
The manuscript by Ma et al. explored the capacity of a bioactive
annexin A1 short peptide to resolve neuroinflammation in a rat
model of exsanguinating cardiac arrest treated by emergency
preservation and resuscitation. The attenuation of cortical cell death
and reduction of several biomarkers of neuroinflammation induced
by the peptide were associated with the increased expression of sirtuin
3 and the upregulation of antioxidant pathways.
Zhang J. et al. indicated that a systemic treatment with simvastatin
reduced polymorphonuclear neutrophil infiltration into brain tissue,
ameliorated brain edema, and reduced proinflammatory mediator
expression in perihematomal area in an animal model of
neuroinflammation after intracerebral hemorrhage.
In conclusion, the Research Topic “Neuroinflammation and its
resolution: frommolecular mechanisms to therapeutic perspectives”
presents the current state of knowledge about the involvement of
microglia and neuroinflammation in neurological disorders and
provides several new perspectives and therapeutic approaches for
the development of novel pharmacological agents aimed at
counteracting neuroinflammatory diseases.
Finally, it should be noted that in six manuscripts (~30%) of
this Research Topic, the antiinflammatory effect of plant-derived
products has been investigated. There is a high rate of failure in
development of drugs for neurological diseases and for AD, in
particular. New treatments are urgently needed, but even if
progress is being made, we probably need to define new targets
and developing new specific agents. In that regard, natural
products could be a valuable source to provide candidates to
be used in CNS diseases.AUTHOR CONTRIBUTIONS
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